Abstract
COVID-19 is caused by SARS-CoV-2, representing a major public health problem. To date no effective treatments have been established. Interferons (IFNs) are being intensively investigated due to their antiviral properties. Among them, Interferon lambda 4 (IFNL4) is known to have antiviral activity against viral infections of the upper respiratory tract, hepatitis C virus (HCV), but also coronaviruses. Importantly, genetic variants of IFNL4 have been associated with spontaneous viral clearance and response to IFNs-based therapies in HCV and other RNA virus infections. However, the presence of IFNL4 variants in COVID-19 is unknown. In this study, we investigated whether the rs12979860 polymorphism within IFNL4 was also associated with COVID-19. Our findings show that the presence of the CC allele of rs12979860 was significantly lower in COVID-19 patients compared to controls without COVID-19 (38% vs 55%, p<0.001). These results were not affected by sex, age, and severity of disease. These findings suggest that the CC allele of rs12979860 may also confer protection against COVID-19. This data may contribute to understanding the mechanisms of disease, the response to IFN-based treatments, and the racial differences observed in COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partially funded by the Junta de Extremadura Grant GR18105 MDRivas is supported by the Spanish Ministerio de Economia, Industria y Competitividad Grant PTA2017-13904-I and FUNDESALUD
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethical Committee for Clinical Research of Caceres
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No additional data but the included in the article. The data that support the findings of this study are available from the corresponding author upon request
